The purpose of this study was to determine the effect of adding CIDAA to a subpopulation of an HMO that also had an RPM program. Patients taking insulin for >6 months with A1Cs >8.0% were selected from 3 cohorts, RPM + CIDAA (Group A) , RPM alone (Group B) and usual care (Group C) and followed for 6 months. Glucose readings of Group A patients, given a Bluetooth-enabled glucometer, were analyzed with dose adjustment recommendations sent to their providers (2 MDs, 1 PA) that they could accept or modify. Health educators contacted Group A and B patients for each RPM glucose value of <70 or >200 mg/dl and counseled them how to avoid subsequent episodes. Non-insulin drugs were not allowed to be added to Group A and B patients. A1C levels were measured at baseline and 6 months. Patient demographics, their A1C responses and alerts are shown in the Table. There were no differences among baseline A1Cs but significant differences from baseline. Groups A vs. B (P = 0.01) and A vs. C (P = 0.001) were significantly different but not B vs. C. All alerts (P = 0.02) and those >200 mg/dl (P = 0.002) were significantly less in Group A vs. B but alerts <70 mg/dl were not. Conclusion: A1C levels fell twice as much without increases in hypoglycemia in poorly controlled type 2 diabetic patients taking insulin whose providers received recommendations for dose changes based on CIDAA every 2-3 weeks compared with RPM alone or usual care.


J.S.Pulicharam: None. J.Davidson: None. M.B.Davidson: Other Relationship; Mellitus Health.


Mellitus Health, Inc

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at